Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

Objective: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab vs. chemotherapy in the first-line setting for patients with advanced non-small-cell lung cancer (NSCLC) from the US payer perspective.Materials and methods: A Markov model wasdeveloped to evaluate the cost and effec...

Full description

Bibliographic Details
Main Authors: Xiaomin Wan, Xiaohui Zeng, Liubao Peng, Ye Peng, Qiao Liu, Lidan Yi, Xia Luo, Qijian Deng, Chongqing Tan
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Pharmacology
Subjects:
nivolumab plus ipilimumab
chemotherapy
cost-effectiveness
non-small cell lung cancer
Markov model
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.580459/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.580459/full

Similar Items